Harvard Health Publications suggests that the decision to medicate behaviors associated with dementia is a heavy burden. Many medications prescribed today help manage problem behaviors, yet suppress the transmission of important neurotransmitters, and can make dementia symptoms worse. The Alzheimer's Association recommends Aricept, Exelon and Reminyl for dementia and Alzheimer's-related memory problems and attention deficits, while for behavior problems, it recommends that care providers should attempt modifications and management first, such as using music or aromatherapy. According to Drug Information Online, drugs to treat dementia are meant to slow the cognitive decline in memory and attention, but they do not reverse or cure the disease.
Aricept
Aricept (donepezil hydrochloride) is approved by the U.S. Food and Drug Administration (FDA) in the treatment of mild, moderate or severe types of Alzheimer's and related dementias. Eisai, the drug's manufacturer, suggests caution be exercised in prescribing this drug for those with gastrointestinal disorders, as Aricept may exacerbate these disorders. Aricept is available in 5 mg and 10 mg once-daily tablets, and the new Aricept ODT is an oral disintegrating tablet made for easier administration.
Exelon
Exelon (rivastigmine hydrogen tartrate) is manufactured by Novartis for the treatment of dementia and Parkinson's disease. FDA and manufacturer recommendation is a twice daily dose ranging from 1.5 mg to 6 mg each. Common side effects, which heed extra consideration include nausea, vomiting, tremors, anorexia and dizziness that could compromise individual health and safety.
Reminyl
Reminyl (galantamine hydrobromide) is FDA approved in the treatment of mild to moderate forms of dementia with options for several delivery methods: a sustained-release once daily tablet, in a dosage of 4, 8 or 12 mg twice per day, or via a pipette, in which case the Reminyl is diluted in a non-alcoholic beverage for ease of administration.
